European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43919610" target="_blank" >RIV/00216208:11120/20:43919610 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.1016/j.ejca.2019.11.014" target="_blank" >https://doi.org/10.1016/j.ejca.2019.11.014</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejca.2019.11.014" target="_blank" >10.1016/j.ejca.2019.11.014</a>

Result language

angličtina

Original language name

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019

Original language description

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts&apos; experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Journal of Cancer

ISSN

0959-8049

e-ISSN

—

Volume of the periodical

126

Issue of the periodical within the volume

February

Country of publishing house

GB - UNITED KINGDOM

Number of pages

18

Pages from-to

141-158

UT code for WoS article

000510619200018

EID of the result in the Scopus database

2-s2.0-85077685143